Wednesday, July 8, 2026

Patent intelligence · US

US 10548905

Amorphous onapristone compositions and methods of making the same

granted A61KA61K31/575A61K9/146A61K9/1635
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 14
Applicant portfolio 3
Patent details — US 10548905
Jurisdiction
US
Status
granted
Grant date
Feb 4, 2020
Expiration
Jan 30, 2040
Claims
7
CPC classes
A61K, A61K31/575, A61K9/146, A61K9/1635
View on Google Patents ↗

Quick answer

US 10548905 (Amorphous onapristone compositions and methods of making the same) is held by CONTEXT BIOPHARMA, INC.. Status: granted. Granted Feb 4, 2020. Expires Jan 30, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
7
CPC classes
A61K, A61K31/575, A61K9/146, A61K9/1635, A61K9/1641, A61K9/1682

More from CONTEXT BIOPHARMA, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 11672762

    Onapristone extended-release compositions and methods

    CONTEXT BIOPHARMA, INC. · Expires Jun 8, 2043

    granted
  2. US 10786461

    Onapristone extended-release compositions and methods

    CONTEXT BIOPHARMA, INC. · Expires Sep 24, 2040

    granted

Frequently asked questions

What is US patent 10548905?

US 10548905 (Amorphous onapristone compositions and methods of making the same) is held by CONTEXT BIOPHARMA, INC.. Status: granted. Granted Feb 4, 2020. Expires Jan 30, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10548905?

CONTEXT BIOPHARMA, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.

When does US 10548905 expire?

Our index shows an expiration date of Jan 30, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.